Focused Ultrasound’s Therapeutic Potential for Blood-Brain Barrier Opening

Tuesday, October 13, 2026

Neurological disease accounts for a large share of the global disease burden. CNS drug development, however, remains unusually difficult. One major reason is anatomical, not pharmacological: even a compound with strong target biology has little therapeutic value if it cannot reach the relevant brain tissue at sufficient concentration.

According to the Paris Brain Institute, more than one in three people will now experience a brain disorder at some point in their lives.1 Risk of the most common disorders often increases with age, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, dementia, and stroke. Taken together, neurological conditions now trail only cardiovascular disease as a cause of death globally.2 Few of them can be cured outright, and their progression steadily narrows a person’s healthspan, the stretch of life spent free of serious disease or disability. As people live longer, they are also likely to work longer, and the combination of lengthier careers with rising CNS disorders is likely to have a noticeable effect on society and the economy.

While the chemistry necessary for treating CNS disorders like Alzheimer’s, Parkinson’s, and oncologic conditions has advanced in recent decades, drug delivery continues to be a challenge. The blood-brain barrier, a tightly regulated layer of endothelial cells lining the brain’s blood vessels, exists to protect neural tissue from pathogens, toxins, and fluctuations in the bloodstream and prevents most small-molecule drugs and nearly all large-molecule biologics from reaching the brain in meaningful concentrations.3

This has made CNS drug development one of the more difficult segments of the pharmaceutical industry.4 Compounds that show strong activity against a target in vitro often fail once formulated for systemic delivery because the drug fails to arrive in sufficient concentration. Researchers have spent decades working around this limitation, chemically modifying compounds to slip past the barrier, exploring intrathecal or intranasal delivery routes, and testing carrier molecules designed to shuttle drugs across.5 Each approach has produced some success, but also real limitations in scale, invasiveness, or applicability across drug classes.

Low-intensity focused ultrasound (LIFU) has emerged as one of the more promising approaches to this problem. When focused ultrasound waves are directed at a specific brain region in the presence of intravenously administered microbubbles, the mechanical energy causes the microbubbles to oscillate against the walls of nearby blood vessels. This interaction loosens the tight junctions of the BBB in that localized area, creating a temporary window during which molecules that would otherwise be excluded can pass into brain tissue.6 Within a period of hours, the barrier reseals and returns to its normal protective function. Because the technique requires no incision and can be targeted with precision to a specific region using MRI or neuronavigation guidance, it has drawn growing interest as a delivery mechanism that could pair with a wide range of existing and investigational CNS therapies rather than requiring new drug chemistry altogether. For drug developers, that precision also raises a practical possibility: reaching therapeutic concentrations in the brain at lower systemic doses, with potential to reduce peripheral toxicity and improve the therapeutic index for some therapies.

The Evidence for LIFU-Mediated Delivery

The clinical evidence for focused ultrasound-mediated BBB opening has progressively addressed three questions: whether the BBB can be opened safely and reversibly, whether opening increases regional therapeutic exposure, and ultimately whether that increased exposure can improve clinically meaningful outcomes.

Early proof-of-concept work in Alzheimer’s disease established the safety profile that much of the subsequent research has built on. A Phase I trial conducted at Sunnybrook Health Sciences Centre in Toronto used MRI-guided focused ultrasound to open the BBB in five patients with early to moderate Alzheimer’s disease, finding the barrier could be safely, reversibly, and repeatedly opened without serious adverse events or cognitive worsening at three months.7 A related Phase II trial targeting the hippocampus and entorhinal cortex, structures notoriously difficult to reach with precision, reported similar safety findings across seventeen treatments in six patients, with BBB closure confirmed within 24 hours of each sonication.8

More recent trials have moved from establishing safety to demonstrating therapeutic benefit. In glioblastoma, where the BBB can limit the effectiveness of systemic chemotherapy, an international multicenter trial combining focused ultrasound-mediated BBB opening with temozolomide reported a median overall survival of 31.3 months; in a subsequent matched analysis, this compared with 19.3 months in an external control cohort, with all 34 treated patients demonstrating confirmed BBB opening and no serious safety signals.9 A separate Phase I/II trial using a nine-emitter implantable ultrasound device with carboplatin in recurrent glioblastoma demonstrated the feasibility of repeated BBB opening.10 More recently, a pediatric diffuse midline glioma study demonstrated repeated BBB opening using a noninvasive, neuronavigation-guided focused ultrasound system, supporting the feasibility of treatment delivery without real-time MRI guidance.11

In Alzheimer’s disease, the most notable recent results come from pairing LIFU with anti-amyloid monoclonal antibody therapy. A first-in-human trial at West Virginia University’s Rockefeller Neuroscience Institute combined focused ultrasound BBB opening with monthly aducanumab infusions in patients with mild Alzheimer’s disease, finding greater amyloid-beta plaque reduction in ultrasound-treated regions compared with untreated regions, with an average 32% reduction in amyloid plaque standardized uptake value ratio after 26 weeks.12 Follow-on work pairing LIFU with lecanemab has reported preliminary safety and feasibility findings, with efficacy data still early.13

Taken together, this body of work spans two of the drug classes most limited by the BBB, small-molecule chemotherapy and large-molecule monoclonal antibodies. It also spans two very different clinical goals, showing encouraging survival outcomes in an aggressive cancer and accelerating clearance of a pathological protein in a neurodegenerative disease, which suggests the underlying mechanism generalizes well beyond any single drug or disease.

Because this modality pairs well with existing drugs, it also has the potential to reshape decisions further upstream, from how combination products are structured to how trials are designed around confirmed regional drug delivery rather than assumed systemic exposure. Confirmed, imaging-verified BBB opening could offer a direct pharmacodynamic readout of target engagement, a measure trial designers could then use to enrich patient selection or guide dose-finding in ways that are difficult to achieve when drug exposure in the brain can only be inferred rather than observed.

Alternatives to LIFU for Drug Delivery

Several other strategies for crossing the BBB have advanced alongside LIFU. Osmotic disruption, typically achieved by infusing hyperosmolar mannitol into the carotid artery, loosens the tight junctions between brain endothelial cells and has a long history of clinical investigation for delivering therapeutics to brain tumors.14 It requires arterial catheterization, though, and affects a broad brain region rather than a precise target, limiting its use to specialized neurointerventional settings. Intranasal delivery avoids the vasculature altogether, routing drugs through the olfactory and trigeminal pathways in the nasal cavity, but absorption is inconsistent and depends heavily on formulation, limiting how much drug reaches deeper brain structures.15

A second category works with the barrier’s own biology. Receptor-mediated transcytosis engineers antibodies or peptides to hijack transport receptors the BBB already uses for molecules like insulin and transferrin, an approach that has shown promise for large-molecule biologics but whose success varies considerably by receptor and antibody design.16 Nanoparticle carriers offer a related route, though variable BBB penetration and challenges related to biodistribution, safety, and manufacturing have slowed clinical translation.17 Each method has found a role for specific drug classes or clinical contexts, but none has yet matched the combination of precision, reversibility, and broad applicability that has made LIFU-mediated BBB opening the focus of so much recent clinical investment.

Research and Regulatory Challenges

While LIFU-mediated BBB opening shows promise, there are still a number of research and regulatory hurdles to clear before the model can be used more widely. For example, most clinical research to date has relied on MRI-guided focused ultrasound, providing precise treatment targeting and imaging confirmation that the barrier has opened as intended. However, every hour of MRI time devoted to a BBB-opening treatment is an hour unavailable for diagnostic imaging, and a single procedure can occupy a scanner for several hours at a time. Under this model, a scanner capable of running dozens of diagnostic studies in a day might accommodate only a handful of BBB-opening treatments. For a chronic condition like Alzheimer’s disease, which would likely require repeated treatments over months or years, sustaining that level of MRI time becomes considerably harder to justify at scale, both for health systems balancing diagnostic demand and for researchers trying to enroll enough patients to run adequately powered trials.

This dependence on MRI infrastructure and specially trained personnel also limits the number of sites capable of delivering treatment and adds meaningful cost and complexity compared to a standard outpatient procedure.18 Portable systems using real-time cavitation mapping instead of MRI are beginning to emerge in early trials, but this work remains at the pilot stage.17 A separate line of development has produced a wearable, steerable transcranial ultrasound platform that registers treatment targets against a patient’s previously acquired MRI scan rather than requiring the patient to remain inside an active MRI scanner during treatment.19 Approaches like these point toward a future generation of focused ultrasound platforms that could extend BBB-opening treatment beyond institutions with dedicated research MRI access, widening both the pool of sites able to conduct trials and, eventually, the pool of patients able to receive treatment without competing directly with diagnostic imaging demand.

Another challenge for LIFU-mediated delivery is administering ultrasound energy through the skull, which introduces substantial attenuation and distortion that can reduce the pressure reaching brain tissue and, in some cases, shift the treatment away from its intended target. Because skull thickness and density vary meaningfully from patient to patient, a dosing protocol calibrated for one individual will not necessarily translate cleanly to another, which complicates efforts to standardize treatment parameters across a broader patient population.20

These technical questions also carry over into regulatory considerations. When focused ultrasound and a specified drug or biologic are intended to be used together to achieve a therapeutic effect, combination-product considerations may apply, requiring an integrated strategy addressing device performance, drug exposure, safety, and clinical efficacy. Researchers examining the introduction of focused ultrasound into neuro-oncology have gone so far as to apply frameworks originally designed to evaluate surgical innovation, arguing that the field lacks a clear, agreed-upon standard for how these trials should be designed and assessed.21

Finally, most of the clinical evidence to date comes from Phase I and small Phase II trials, often involving single digits to a few dozen patients treated over a period of months. That is appropriate for an early-stage modality, but it also means that longer-term safety data, particularly for chronic conditions like Alzheimer’s disease that may require repeated sessions over extended periods rather than a limited oncology treatment course, still needs to be established before LIFU-mediated BBB opening can move from a promising intervention into routine clinical practice.22

The Future of CNS Drug Delivery

CNS disease treatment exists at the center of several complex, interconnected problems that make it a unique challenge to research, dominated by the key obstacle of delivery. In many ways, the BBB has shaped the entire trajectory of CNS drug development over the last several decades as time and again, compounds capable of acting on a known disease target fail because the drug never arrives in the brain in sufficient concentration to work. Meanwhile, the stakes grow higher as populations age and longevity increases, increasing the risks of CNS disease.

LIFU-mediated BBB opening addresses the problem of delivery directly, and the evidence gathered so far reflects its promise as a new delivery modality. The technique has demonstrated safety and reversibility across multiple patient populations, shown encouraging survival outcomes in an aggressive brain cancer, and accelerated the clearance of pathological protein in a neurodegenerative disease, all without requiring new drug chemistry. Few approaches to the BBB problem can claim that combination of precision, reversibility, and applicability across such different drug classes and clinical goals.

Real challenges remain. MRI-related infrastructure requirements, skull-based dosing variability, and regulatory complexity around drug-device development are not minor details to be resolved later. Solving them will determine how quickly this technology moves from a handful of specialized research centers into broader clinical use. However, continued engineering and clinical development are increasingly focused on addressing these challenges, and the underlying science supports continued progress in this direction. Portable, MRI-independent platforms already in development suggest that the infrastructure bottleneck in particular may prove more solvable than it first appears.

Given that CNS medicine has long struggled not only with identifying viable compounds but also with getting them to the brain in adequate concentration, a method that opens the barrier safely, reversibly, and with a growing evidentiary basis merits serious attention as a delivery platform for future CNS therapies. As the research matures and access to the technology broadens, LIFU-mediated BBB opening may reasonably be expected to play a substantial role in how CNS therapeutics reach the brain going forward.

References

  1. World Brain Health Forum 2026. Brain health: a major challenge of the 21st century. Paris Brain Institute. Updated January 12, 2026. Accessed August 5, 2026. https://parisbraininstitute.org/news/world-brain-health-forum-2026
  2. Steinmetz J, Seeher K, Schiess N et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology. 2024;23 (4): 344-381. doi:10.1016/S1474-4422(24)00038-3
  3. Pardridge W.M. The blood-brain barrier: Bottleneck in brain drug development. Neurotherapeutics 2, 3–14 (2005). doi: 10.1602/neurorx.2.1.3
  4. Pardridge W.M. Blood-brain barrier delivery. Drug Discovery Today. 2007;12(1–2). doi: 10.1016/j.drudis.2006.10.013
  5. Gabathuler R. Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiology of Disease. 2010;37(1):48-57. doi:10.1016/j.nbd.2009.07.028.
  6. Noel RL, Kugelman T, Karakatsani ME, et al. Safe focused ultrasound-mediated blood-brain barrier opening is driven primarily by transient reorganization of tight junctions. Commun Eng. 2026;5(1):58. doi: 10.1038/s44172-026-00597-5
  7. Lipsman N, Meng Y, Bethune AJ, et al. Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound. Nat Commun. 2018 Jul 25;9(1):2336. doi: 10.1038/s41467-018-04529-6
  8. Rezai AR, Ranjan M, D’Haese PF, et al. Noninvasive hippocampal blood-brain barrier opening in Alzheimer’s disease with focused ultrasound. Proc Natl Acad Sci USA. 2020;117(17):9180-9182. doi: 10.1073/pnas.2002571117
  9. Woodworth GF, Anastasiadis P, Ozair A, et al. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2025;26(12):1651-1664. doi:10.1016/S1470-2045(25)00492-9
  10. Carpentier A, Stupp R, Sonabend AM, et al. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial. Nat Commun. 2024;15(1):1650. doi:10.1038/s41467-024-45818-7
  11. Wu CC, Szalontay L, Pouliopoulos AN, et al. Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma. Sci Transl Med. 2025;17(824):eadq6645. doi:10.1126/scitranslmed.adq6645
  12. Rezai AR, D’Haese PF, Finomore V, et al. Ultrasound blood-brain barrier opening and aducanumab in Alzheimer’s disease. N Engl J Med. 2024;390(1):55-62. doi:10.1056/NEJMoa2308719
  13. Rezai AR, D’Haese PF, Finomore V, et al. Combination of focused ultrasound blood-brain barrier opening with Lecanemab therapy in mild Alzheimer’s disease. Alzheimers Dement. 2026;21(suppl 2):e106394. doi:10.1002/alz70856_106394.
  14. Kandimalla KK. Drug delivery strategies to cross, target, or bypass the blood-brain barrier. Mol Pharm. 2025;22(11):6395-6397. doi:10.1021/acs.molpharmaceut.5c01417
  15. Xu K, Duan S, Wang W, et al. Nose-to-brain delivery of nanotherapeutics: Transport mechanisms and applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16(2):1956. doi:10.1002/wnan.1956
  16. Kucharz K, Kristensen K, Johnsen KB, et al. Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles. Nat Commun. 2021;12(1):4121. doi:10.1038/s41467-021-24323-1
  17. Burgess A, Shah K, Hough O, Hynynen K. Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev Neurother. 2015;15(5):477-491. doi:10.1586/14737175.2015.1028369
  18. Bae S, Liu K, Pouliopoulos AN, et al. Transcranial blood-brain barrier opening in Alzheimer’s disease patients using a portable focused ultrasound system with real-time 2-D cavitation mapping. Theranostics. 2024;14(11):4519-4535. doi:10.7150/thno.94206
  19. Bawiec CR, Hollender PJ, Ornellas SB, et al. A wearable, steerable, transcranial low-intensity focused ultrasound system. J Ultrasound Med. 2025;44(2):239-261. doi:10.1002/jum.16600
  20. Durham PG, Butnariu A, Alghorazi R, Pinton G, Krishna V, Dayton PA. Current clinical investigations of focused ultrasound blood-brain barrier disruption: a review. Neurotherapeutics. 2024;21(3):e00352. doi:10.1016/j.neurot.2024.e00352
  21. Thavarajasingam SG, Kilgallon JL, Ramsay DSC, et al. Methodological and ethical challenges in the use of focused ultrasound for blood-brain barrier disruption in neuro-oncology. Acta Neurochir (Wien). 2023;165(12):4259-4277. doi:10.1007/s00701-023-05782-5
  22. Fishman PS, Fischell JM. Focused ultrasound mediated opening of the blood-brain barrier for neurodegenerative diseases. Front Neurol. 2021;12:749047. doi:10.3389/fneur.2021.749047

About the Author

Davinder (“Dave”) Ramsingh, MD, is Chief Medical Officer at Openwater. A UCLA-trained cardiac anaesthesiologist, he has more than 20 years of experience in ultrasound and sensor technologies. His work focuses on the clinical translation of non-invasive therapeutic and monitoring technologies, including low-intensity focused ultrasound (LIFU). Before joining Openwater, he held clinical and medical affairs leadership roles at companies developing ultrasound and critical care monitoring technologies.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!

  • <<
  • >>

Join the Discussion